Analysts Set Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) PT at $559.61

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has been assigned an average recommendation of “Moderate Buy” from the twenty-five brokerages that are covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and twenty-two have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $559.6087.

A number of analysts have recently weighed in on the company. Weiss Ratings upgraded Vertex Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Friday, July 17th. Royal Bank Of Canada boosted their price target on shares of Vertex Pharmaceuticals from $543.00 to $570.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. Barclays upped their price target on shares of Vertex Pharmaceuticals from $607.00 to $615.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Morgan Stanley lifted their price objective on shares of Vertex Pharmaceuticals from $612.00 to $616.00 and gave the company an “overweight” rating in a research report on Tuesday, May 5th. Finally, Truist Financial boosted their target price on shares of Vertex Pharmaceuticals from $542.00 to $560.00 and gave the company a “buy” rating in a research note on Monday, July 13th.

Insider Buying and Selling

In other news, EVP Ourania Tatsis sold 1,500 shares of the stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $524.99, for a total value of $787,485.00. Following the completion of the transaction, the executive vice president owned 45,321 shares of the company’s stock, valued at approximately $23,793,071.79. This represents a 3.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Carmen Bozic sold 6,988 shares of the firm’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $450.00, for a total value of $3,144,600.00. Following the transaction, the chief marketing officer directly owned 26,088 shares in the company, valued at $11,739,600. This trade represents a 21.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 17,452 shares of company stock valued at $8,103,997 in the last three months. 0.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Vertex Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Community Financial Services Group LLC acquired a new position in shares of Vertex Pharmaceuticals during the second quarter valued at approximately $26,000. Elevation Wealth Partners LLC lifted its position in Vertex Pharmaceuticals by 103.7% in the second quarter. Elevation Wealth Partners LLC now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 28 shares during the period. Motiv8 Investments LLC bought a new position in Vertex Pharmaceuticals during the 4th quarter valued at $26,000. Swiss RE Ltd. acquired a new position in shares of Vertex Pharmaceuticals during the 4th quarter valued at $28,000. Finally, Eagle Bay Advisors LLC bought a new stake in shares of Vertex Pharmaceuticals in the 4th quarter worth $29,000. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Price Performance

Shares of VRTX opened at $470.72 on Thursday. The business’s fifty day moving average price is $471.34 and its 200 day moving average price is $460.44. Vertex Pharmaceuticals has a 12-month low of $362.50 and a 12-month high of $533.67. The stock has a market capitalization of $119.47 billion, a PE ratio of 27.92, a price-to-earnings-growth ratio of 2.15 and a beta of 0.30.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, August 3rd. The pharmaceutical company reported $4.73 earnings per share for the quarter, missing the consensus estimate of $4.74 by ($0.01). Vertex Pharmaceuticals had a net margin of 35.51% and a return on equity of 23.86%. The business had revenue of $3.33 billion for the quarter, compared to the consensus estimate of $3.23 billion. During the same quarter in the previous year, the firm earned $4.52 EPS. The firm’s revenue for the quarter was up 12.5% on a year-over-year basis. As a group, research analysts anticipate that Vertex Pharmaceuticals will post 17.01 earnings per share for the current fiscal year.

Key Stories Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Second-quarter revenue rose 12.5% year over year to approximately $3.33 billion, exceeding Wall Street expectations. Growth was supported by continued demand for Vertex’s cystic fibrosis medicines, as well as contributions from sickle-cell disease, beta thalassemia and acute-pain treatments. Vertex Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Vertex raised its full-year 2026 revenue outlook to $13.1 billion-$13.2 billion, above the roughly $13.0 billion analyst consensus. The higher forecast reflects sustained strength in cystic fibrosis drug sales. Vertex raises annual revenue forecast
• Positive Sentiment: Profitability remained strong, with a 35.5% net margin and operating cash flow of approximately $1.4 billion. Vertex also highlighted strong growth from CASGEVY, its gene-edited therapy developed with CRISPR Therapeutics, and its expanding non-cystic-fibrosis pipeline.
• Neutral Sentiment: Vertex announced an agreement to acquire Crinetics Pharmaceuticals for approximately $10.0 billion in equity value, or about $8.8 billion net of estimated cash. The transaction would add PALSONIFY (paltusotine) and establish rare endocrine diseases as another major business area, but its scale may increase near-term execution and valuation risk. Crinetics acquisition announcement
• Negative Sentiment: Adjusted EPS was $4.73, narrowly below the $4.74 consensus; another data provider cited a $4.79 estimate. The modest miss likely drove the negative reaction despite revenue outperforming expectations and EPS increasing from $4.52 a year earlier. Vertex Pharmaceuticals Q2 Earnings Lag Estimates

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.